Ñî¹óåú´«Ã½Ò•îl

High and rising levels of tetracycline resistance globally will likely limit the ability of doxycycline post-exposure prophylaxis (doxyPEP) to prevent gonorrhea infections, according to a study published today in JAC-Antimicrobial Resistance. (Dall, 7/9)

The symptoms can include nerve pain, emotional numbness and sexual dysfunction and can last for years after stopping the drugs. Patients are pushing for recognition and more research. (Corwin, 7/9)

A study of more than 70,000 US pregnancies suggests a commonly used antibiotic for urinary tract infections (UTIs) may be tied to increased risk of congenital malformations when taken during the first trimester of pregnancy. (Dall, 7/9)

Mendaera announced Tuesday its Focalist handheld robotic needle placement device has received clearance from the Food and Drug Administration. The device used ultrasound to help clinicians guide needles during procedures that require reaching organs, performing biopsies and delivering treatment. (Dubinsky, 7/8)

Cogent Biosciences said Monday that its experimental drug reduced the symptoms of a chronic immune disorder called indolent systemic mastocytosis. The results mean the drug achieved the goals of a Phase 3 study, but a comparison to a rival treatment from Blueprint Medicines remains muddled. (Feuerstein, 7/7)